Floatz logo

Recombinant L-Ifn Adenovirus

Lung Cancer

Shanghai Fengxian District Central Hospitalgene_therapyEarly Phase 1Active
C
34/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
65/ 100

Competitive context

303 Active assets in the Lung Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
SystImmune Inc.
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Vermont
Phase 4BB
PROPOFOL
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Nivolumab
University of Chicago
Phase 4BB

View all 50 →

Same molecule, other indications

Recombinant L-Ifn Adenovirus is also rated in:

glioblastomaDormant
C
Indicative ·
39 / 100
View asset →
cervical carcinomaDormant
C
Indicative ·
39 / 100
View asset →
ovarian carcinomaDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →